The global spinal cord injury therapeutics market comprises therapeutics used for the treatment of spinal cord injury such as corticosteroids, non-steroidal anti-inflammatory drugs (NSAID’S), muscle relaxants, and anti-depressants. There are two types of spinal cord injuries including complete spinal cord injury and incomplete spinal cord injury and various causes of spinal cord injuries include brain injury, trauma, loss of blood supply to spinal cord, and compression in spinal cord due to tumor or infections.
Market Dynamics
Key players are focusing on product approvals to strengthen their position in the global spinal cord injury therapeutics market. For instance, in September 2020, AbbVie Inc., received an orphan drug and fast track designation from the U.S. Food and Drug Administration for Elezanumab, an investigational monoclonal antibody RGMa inhibitor for the treatment of spinal cord injury.
Key features of the study:
- This report provides in-depth analysis of the global spinal cord injury therapeutics market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global spinal cord injury therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Dr. Reddy's Laboratories Ltd., Zydus Cadila, ReNetX Bio, Inc., InVivo Therapeutics Holdings, Lineage Cell Therapeutics, Inc., Kringle Pharma, Inc., Acorda Therapeutics, Inc., Bioaxone Biosciences, Inc., RespireRx Pharmaceuticals Inc., NervGen, Rising Pharmaceuticals, Inc., ScieGen Pharmaceuticals, Inc., MSN Laboratories Private Limited, and Lannett Co Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global spinal cord injury therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spinal cord injury therapeutics market
Detailed Segmentation:
- Global Spinal Cord Injury Therapeutics Market, By Injury Type:
- Complete Spinal Cord Injury
- Incomplete Spinal Cord Injury
- Global Spinal Cord Injury Therapeutics Market, By Drug Type:
- Corticosteroids
- Muscle Relaxants and Anti-spastic drugs
- Non-steroidal Anti-inflammatory drugs (NSAIDs)
- Anti-depressants
- Anticonvulsants
- Others
- Global Spinal Cord Injury Therapeutics Market, By Application:
- Autonomic Dysreflexia (AD)
- Spasticity & Inflammation
- Pain Management
- Depression
- Global Spinal Cord Injury Therapeutics Market, By Route of Administration:
- Global Spinal Cord Injury Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Spinal Cord Injury Therapeutics Market, By Region:
- North America
- By Injury Type
- Complete Spinal Cord Injury
- Incomplete Spinal Cord Injury
- By Drug Type
- Corticosteroids
- Muscle Relaxants and Anti-spastic drugs
- Non-steroidal Anti-inflammatory drugs (NSAIDs)
- Anti-depressants
- Anticonvulsants
- Others
- By Application
- Autonomic Dysreflexia (AD)
- Spasticity & Inflammation
- Pain Management
- Depression
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Injury Type
- Complete Spinal Cord Injury
- Incomplete Spinal Cord Injury
- By Drug Type
- Corticosteroids
- Muscle Relaxants and Anti-spastic drugs
- Non-steroidal Anti-inflammatory drugs (NSAIDs)
- Anti-depressants
- Anticonvulsants
- Others
- By Application
- Autonomic Dysreflexia (AD)
- Spasticity & Inflammation
- Pain Management
- Depression
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Injury Type
- Complete Spinal Cord Injury
- Incomplete Spinal Cord Injury
- By Drug Type
- Corticosteroids
- Muscle Relaxants and Anti-spastic drugs
- Non-steroidal Anti-inflammatory drugs (NSAIDs)
- Anti-depressants
- Anticonvulsants
- Others
- By Application
- Autonomic Dysreflexia (AD)
- Spasticity & Inflammation
- Pain Management
- Depression
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Injury Type
- Complete Spinal Cord Injury
- Incomplete Spinal Cord Injury
- By Drug Type
- Corticosteroids
- Muscle Relaxants and Anti-spastic drugs
- Non-steroidal Anti-inflammatory drugs (NSAIDs)
- Anti-depressants
- Anticonvulsants
- Others
- By Application
- Autonomic Dysreflexia (AD)
- Spasticity & Inflammation
- Pain Management
- Depression
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Injury Type
- Complete Spinal Cord Injury
- Incomplete Spinal Cord Injury
- By Drug Type
- Corticosteroids
- Muscle Relaxants and Anti-spastic drugs
- Non-steroidal Anti-inflammatory drugs (NSAIDs)
- Anti-depressants
- Anticonvulsants
- Others
- By Application
- Autonomic Dysreflexia (AD)
- Spasticity & Inflammation
- Pain Management
- Depression
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Injury Type
- Complete Spinal Cord Injury
- Incomplete Spinal Cord Injury
- By Drug Type
- Corticosteroids
- Muscle Relaxants and Anti-spastic drugs
- Non-steroidal Anti-inflammatory drugs (NSAIDs)
- Anti-depressants
- Anticonvulsants
- Others
- By Application
- Autonomic Dysreflexia (AD)
- Spasticity & Inflammation
- Pain Management
- Depression
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Teva Pharmaceutical Industries Ltd.*
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AbbVie Inc.
- Pfizer Inc.
- Reddy's Laboratories Ltd.
- Zydus Cadila
- ReNetX Bio, Inc.
- InVivo Therapeutics Holdings
- Lineage Cell Therapeutics, Inc.
- Kringle Pharma, Inc.
- Acorda Therapeutics, Inc.
- Bioaxone Biosciences, Inc.
- RespireRx Pharmaceuticals Inc.
- NervGen
- Rising Pharmaceuticals, Inc.
- ScieGen Pharmaceuticals, Inc.
- MSN Laboratories Private Limited
- Lannett Co Inc.
“*” marked represents similar segmentation in other categories in the respective section.
